Suggested remit - To appraise the clinical and cost effectiveness of abemaciclib within its marketing authorisation for treating hormone-receptor positive, HER2-negative breast cancer.
Status In progress
Process STA
ID number 1339

Email enquiries


Key events during the development of the guidance:

Date Update
19 October 2017 - 16 November 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
23 September 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance